Gene therapies for inherited retinal diseases
Search documents
Opus Genetics, Inc. (IRD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Seeking Alpha· 2026-01-15 20:26
PresentationSusmita Roy Good morning, everyone. My name is Susmita Roy, and I'm an associate on the JPMorgan Healthcare Investment Banking team. On behalf of JPMorgan, I would like to thank everyone for attending the Healthcare Conference this year. And I'm pleased and honored to introduce Opus Genetics for the company presentation today. A bit about Opus Genetics. It is a clinical stage biopharmaceutical company developing gene therapies for inherited retinal diseases, trading under the ticker symbol IRD. ...